Bill Gross warns on gold momentum as regional bank stocks tumble
Investing.com -- Raymond James revealed in a note to clients on Tuesday that it has added Cogent Biosciences and Dime Community Bancshares to its Analyst Current Favorites list, highlighting differentiated growth opportunities in biotechnology and banking.
The firm’s analysts explained that Cogent Biosciences was named a top pick on the back of its lead drug candidate, bezuclastinib.
Raymond James said that although Blueprint Medicine’s Ayvakit pioneered the systemic mastocytosis market, “we believe Cogent’s bezuclastinib possesses a differentiated profile and best-in-class potential in this large and expanding market.”
The firm cited “strong clinical data and consistent KOL feedback,” pointing to meaningful efficacy and safety benefits.
With pivotal data in hand and a new drug application filing expected by year-end 2025, Raymond James argued the launch could “surprise to the upside.” The analysts add that additional upside could come from late-stage trial results in second-line gastrointestinal stromal tumour, expected in the fourth quarter.
Dime Community Bancshares was also added, with Raymond James highlighting the bank’s earnings outlook amid shifting interest rates.
The firm said “core deposit growth and expected lower short-term interest rates (~5 bp of NIM expansion per 25 bp cut) should drive a material improvement in Dime Community Bankshares Inc.’s earnings for 2026.”
The analysts noted that a loan portfolio shift from commercial real estate to commercial and industrial lending, alongside a more favourable rate backdrop, should bolster valuation.
Raymond James also pointed to Dime’s attractive positioning versus peers, noting that “with the stock near TBV (1.2x), and at a discount to peers on a P/E basis (7.8x our 2026E versus small cap banks at 10.3x), we make Dime Community Bancshares, Inc. our Analyst Current Favorite.”
The analysts stated that its list is updated as changes occur and reflects analysts’ highest-conviction buy-rated ideas.